CMRX (Chimerix) Marketable Securities : $112.59 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chimerix Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Chimerix's Marketable Securities for the quarter that ended in Sep. 2024 was $112.59 Mil.

Chimerix's annual Marketable Securities increased from Dec. 2021 ($72.97 Mil) to Dec. 2022 ($191.49 Mil) but then declined from Dec. 2022 ($191.49 Mil) to Dec. 2023 ($155.17 Mil).

Chimerix Marketable Securities Historical Data

The historical data trend for Chimerix's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Marketable Securities Chart

Chimerix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

96.57

31.97

72.97

191.49

155.17

Chimerix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Marketable Securities	Get a 7-Day Free Trial															180.36	155.17	140.00	132.51	112.59

Chimerix Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Chimerix (NAS:CMRX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Chimerix Marketable Securities Related Terms

Thank you for viewing the detailed overview of Chimerix's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimerix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

CXF:Germany

Address

2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713

Website

https://www.chimerix.com

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Executives

Michael T. Andriole	officer: Chief Business Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
David Jakeman	officer: Principal Accounting Officer	C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Fred A Middleton	director	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Michael A. Sherman	director, officer: Chief Executive Officer	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Cantex Pharmaceuticals, Inc.	10 percent owner	1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed	officer: Chief Medical Officer	C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols	officer: Chief Medical Officer	C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz	officer: Principal Executive Officer	2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey	officer: Chief Medical Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713